Điều Trị Hỗ Trợ Sau Phẫu Thuật Cho Ung Thư Tuỵ Có Thể Cắt Bỏ Bằng Gemcitabin và Miễn Dịch Thụ Động

1999, Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database, J Am Coll Surg, 189, 1, 10.1016/S1072-7515(99)00075-7

2007, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial, JAMA, 297, 267, 10.1001/jama.297.3.267

1990, Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin, J Biol Chem, 265, 15286, 10.1016/S0021-9258(18)77254-2

1999, Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma, Hepatogastroenterology, 46, 2240

2008, Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1, Oncol Rep, 20, 155

1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403

2012, Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro, Anticancer Res, 32, 5363

2009, A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer, Br J Cancer, 101, 908, 10.1038/sj.bjc.6605256

2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6

1998, 2′-2′-difluorodeoxycytidine: in vitro effects on cell-mediated immune response, Anticancer Res, 18, 3597

2009, Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice, Int Immunopharmacol, 9, 900, 10.1016/j.intimp.2009.03.015

2005, Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas, Cancer Immunol Immunother, 54, 915, 10.1007/s00262-004-0638-1

1990, Patterns of failure after curative resection of pancreatic carcinoma, Cancer, 66, 56, 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6

1997, Recurrence after resection for ductal adenocarcinoma of the pancreas, World J Surg, 21, 195, 10.1007/s002689900215

1988, In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells, Cell Immunol, 115, 179, 10.1016/0008-8749(88)90172-4

1990, In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats, Cell Immunol, 129, 288, 10.1016/0008-8749(90)90205-6

2012, The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion, Front Physiol, 3, 270

2002, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J Immunol, 169, 2756, 10.4049/jimmunol.169.5.2756

2012, Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth, Cancer Immunol Immunother, 61, 1373, 10.1007/s00262-011-1178-0

2011, Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13, Cancer Immunol Immunother, 60, 1419, 10.1007/s00262-011-1028-0

2013, Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study, PLoS One, 8, e54824, 10.1371/journal.pone.0054824

2009, Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy, Cancer Immunol Immunother, 58, 49, 10.1007/s00262-008-0523-4

2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J Exp Med, 207, 2187, 10.1084/jem.20100643

2013, Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas — a retrospective tumor marker prognostic study, Int J Surg, 11, 1067, 10.1016/j.ijsu.2013.10.005

2000, Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators, J Gastrointest Surg, 4, 567, 10.1016/S1091-255X(00)80105-5

2007, Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer, J Gastrointest Surg, 11, 1549, 10.1007/s11605-007-0243-7

2009, Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma, Eur J Surg Oncol, 35, 600, 10.1016/j.ejso.2008.12.006

2012, Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer, Med Oncol, 29, 3092, 10.1007/s12032-012-0226-8

2004, CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma, Pancreas, 28, e26, 10.1097/00006676-200401000-00023

2009, Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer, Clin Cancer Res, 15, 6511, 10.1158/1078-0432.CCR-09-0565

2013, Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells, Cell Stem Cell, 12, 31, 10.1016/j.stem.2012.12.006

2008, Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes, Anticancer Res, 28, 379

2014, Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer, J Transl Med, 12, 175, 10.1186/1479-5876-12-175